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Approximately 5–10% of asthmatic patients worldwide suffer from severe asthma. 
Experimental and clinical studies have demonstrated that IL-13 is an important cytokine 
in chronic airways inflammation. IL-13 is involved in Th2 inflammation and has been 
identified as a possible therapeutic target in the treatment of asthma. Two different human 
monoclonal antibodies (mAbs) anti-IL-13 (tralokinumab and lebrikizumab) block binding 
and signaling of IL-13 to its receptors, IL-13Rα1 and IL-13Rα2. Several randomized, 
double-blind, placebo-controlled multicenter studies have evaluated the safety and 
efficacy of tralokinumab and lebrikizumab in the treatment of adult patients with severe 
asthma, but all have failed to meet their primary endpoints. No serious adverse events 
related to the treatment with these anti-IL-13 mAbs have been reported in these studies. 
These negative clinical results contrast with positive findings from blocking IL-13 signaling 
in experimental models of asthma, raising doubts about the transferrable value of some 
models. Interestingly, dupilumab, a mAb which blocks both IL-4 and IL-13 signaling 
reduces exacerbation rates and improves lung function in severe asthmatics. These 
results suggest that IL-4 and IL-13 share some, but not all functional activities in airway 
inflammation. Tralokinumab might show efficacy in a highly selected cohort of asthmatics 
characterized by overexpression of IL-13.
Keywords: asthma, biologics, chronic rhinosinusitis, interleukin 4, interleukin 13, nasal polyposis, tralokinumab
INTRODUCTION
Bronchial asthma is a chronic inflammatory disorder of the airways characterized by reversible 
airflow obstruction, bronchial hyperreactivity (BHR), mucus overproduction, angiogenesis, and 
airway remodeling (Detoraki et al., 2010; Holgate et al., 2015). Asthma is a common disorder 
resulting in substantial morbidity, healthcare expenditure, and death (Lang and Polansky 1994; 
Lange et al., 1996). Worldwide, up to 300 million people are affected by asthma, making it one of 
the most common chronic diseases (World Health Organization. Global surveillance, prevention, 
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and control of chronic respiratory diseases. http://www.
who.int/gard/publications/GARD/2007) and approximately 
250,000 people die from asthma each year (Lozano et al., 
2012). In the majority of patients, asthma can be controlled by 
combinations of inhaled glucocorticoids (ICS), short- or long-
acting ß2-adrenergic agonists (LABA), long-acting muscarinic 
antagonists, and leukotriene receptor antagonists, according 
to the Global Initiative for Asthma (GINA) guidelines (GINA 
http://www.ginasthma.org/pdf). However, in approximately 
15% of patients, the disease is refractory to conventional 
treatments (Chachi et al., 2013; Chachi et al., 2017) and results 
in hospital admissions due to severe exarcerbations (Sekiya et 
al., 2016; Kerkhof et al., 2018).
As with many chronic inflammatory diseases, clinicians now 
realize that the traditional classification of asthma has been 
an oversimplification (Marone et al., 2005). Different asthma 
phenotypes, each with distinct pathophysiology, are now being 
defined as asthma endotypes (Wenzel 2012; Fahy 2015; Hinks 
et al., 2016; Terl et al., 2017). The heterogeneity of different 
forms of asthma reflects the involvement of different immune 
cell populations and inflammatory mediators (Bagnasco et al., 
2017; Varricchi et al., 2017; Marone et al., 2019). Asthma can be 
classified according to two major endotypes: “T2-high” asthma is 
characterized by increased levels of type 2 inflammation mainly 
mediated by mast cells, eosinophils, basophils, T-helper 2 cells, 
group 2 innate lymphoid cells (ILC2s), and immunoglobulin E 
(IgE)-producing B cells (Fahy, 2015). Patients with T2-high asthma 
have eosinophilia and other signs of type 2 inflammation including 
high levels of IL-4 and IL-13 (Fahy, 2015; Kaur and Chupp, 2019). 
Increased blood and sputum levels of eosinophils, serum IgE, and 
the fraction of exhaled nitric oxide (FeNO) have been associated 
with the mechanisms of T2-high asthma (Gandhi et al., 2017; 
Robinson et al., 2017). Another feature is the high expression of the 
prostaglandin D2 receptor chemoattractant receptor-homologous 
molecule (CRTH2) on Th2 lymphocytes (Cosmi et al., 2000; 
Marone et al., 2019). “T2-low” asthma is less well characterized 
and may include several different endotypes (Wenzel, 2012; Choy 
et al., 2015; Fahy, 2015; Pepper et al., 2017). It has been suggested 
that Th1 and Th17 pathways and neurogenic inflammation may be 
involved (Ricciardolo et al., 2017; Samitas et al., 2017).
Levels of IgE, blood eosinophils and FeNO can be useful to guide 
the selection of monoclonal antibodies (mAbs) in the treatment of 
different forms of severe uncontrolled asthma. For example, several 
studies have demonstrated the safety and efficacy of mAbs blocking 
IL-5 (i.e., mepolizumab and reslizumab) for treatment of patients 
with severe eosinophilic asthma (Bel et al., 2014; Ortega et al., 2014; 
Bjermer et al., 2016; Khatri et al., 2019). Benralizumab, a mAb 
against IL-5Rα, expressed on the surface of human eosinophils 
(Varricchi et al., 2018a), is particularly effective in patients with 
severe asthma with high blood eosinophils (FitzGerald et al., 2016; 
FitzGerald et al., 2018). Because IgE and the high affinity receptor 
for IgE (FcεRI) play a central role in atopic asthma (Varricchi et al., 
2018d; Borriello et al., 2019; Varricchi et al., 2019), a mAb anti-
IgE (omalizumab) is indicated for the treatment of patients (aged 
≥ 12 years) with moderate-to-severe uncontrolled allergic asthma 
(Samitas et al., 2015; Hew et al., 2016). Serum concentrations of 
IgE are used to guide this treatment.
IL-4 and IL-13 were among the first identified cytokines 
orchestrating Th2 inflammation (Macchia et al., 2015; 
McCormick and Heller 2015; Bagnasco et al., 2016). IL-4 and 
IL-13 are potent mediators of type 2 inflammation with both 
overlapping and distinct functions. Pascolizumab, a mAb 
selectively blocking IL-4, failed to produce positive effects (Hart 
et al., 2002). Two mAbs blocking IL-13 (i.e., anrukinzumab, 
lebrikizumab) have shown marginal effects in the treatment of 
asthmatic patients (Corren et al., 2011; Gauvreau et al., 2011; 
Hanania et al., 2015; Bagnasco et al., 2016; Hanania et al., 2016). 
Another mAb anti-IL-13 (i.e., tralokinumab, AstraZeneca) 
failed to reduce asthma exacerbation rate in severe uncontrolled 
asthmatics (Piper et al., 2013; Brightling et al., 2015; Panettieri 
et al., 2018; Russell et al., 2018). Considering the individual 
relevance of IL-4 and IL-13 in the pathogenesis of asthma, these 
results are surprising and intriguing. A simplistic explanation 
is that individual blockade of IL-4 or IL-13 is insufficient to 
inhibit the complex orchestration of allergic inflammation 
and clinical consequences in severe asthma. This hypothesis 
is indirectly supported by the efficacy of dupilumab, which 
inhibits both IL-4 and IL-13 signaling mediated by IL-4Rα, in 
patients with severe uncontrolled asthma (Castro et al., 2018; 
Rabe et al., 2018).
In this review we analyze the biological and immunological 
effects of IL-13 in the context of experimental models of asthma 
and in asthmatic patients. Despite promising findings in several 
experimental models of allergic inflammation, the results of 
multicenter studies evaluating the efficacy of anti-IL-13 mAbs 
in patients with asthma were surprisingly negative. Possible 
explanations of these discrepancies are discussed.
Biological and Immunological effects of 
Interleukin 13
IL-13 is a pleiotropic cytokine originally cloned from activated 
human T-lymphocytes (Minty et al., 1993). The human IL13 
gene is located on chromosome 5q31-33 in the cluster of genes 
encoding IL-4, IL-3, IL-5, IL-9, and granulocyte-macrophage 
colony-stimulating factor (GM-CSF). The gene encoding IL-13 is 
upstream of the IL4 gene, leading to the speculation that these 
genes arose as a duplication event during evolution. However, 
IL-13 has only 25% homology with IL-4 thus explaining why 
these cytokines share some, but not all functional properties. 
IL-13 can be produced by stimulated Th2 cells (de Vries 1998), 
B lymphocytes (Hajoui et al., 2004), CD8+ cells (Dakhama 
et al., 2013), type 2 ILCs (Jia et al., 2016), alveolar macrophages 
Abbreviations: ACQ, asthma control questionnaire; AHR, airway 
hypersensitivity; BAL, bronchoalveolar lavage; CRSwNP, chronic sinusitis with 
nasal polyps; DC, dendritic cell; ERK, extracellular signal-regulated kinase; DPP-
4, dipeptidyl peptidase-4; FcεRI, high affinity receptor for IgE; FeNO, fraction 
of exhaled nitric oxide; FEV1, forced expiratory volume in the first second; ILC, 
innate lymphoid cell; JAK, Janus kinase; LABA, long-acting β2-agonist; ICS, 
inhaled glucocorticoid; mAb, monoclonal antibody; OVA, ovalbumin; PEF, peak 
expiratory flow; PGD2, prostaglandin D2; PRO, patient-reported outcomes; 
SABA, short-acting β2-agonist; STAT6, signal transducer and activator of 
transcription; TSLP, thymic stromal lymphopoietin; TYK2, tyrosine kinase 2; 
VCAM, vascular cell adhesion molecule.
Frontiers in Pharmacology | www.frontiersin.org December 2019 | Volume 10 | Article 1387
IL-13 Pathophysiology in Asthma Marone et al.
3
(Hancock et al., 1998), human mast cells (Fushimi et al., 1998), 
and basophils (Ochensberger et  al., 1996; Redrup et al., 1998; 
Borriello et al., 2015).
Figure 1 schematically illustrates the complex receptor 
system which mediates the signaling of IL-4 and IL-13. The 
IL-4Rα subunit is a component of both the type I and type II 
receptors. Type I receptors are composed of the IL-4Rα subunit 
complexed with common γ chain (γc); this receptor binds to 
IL-4 and is expressed on cells of hematopoietic stem cell origin. 
The type II receptor complex consists of IL-4Rα partnering with 
IL-13Rα1 and is found on many non-hematopoietic cells, such 
as bronchial epithelial cells, smooth muscle cells, fibroblasts, 
and keratinocytes (Akaiwa et al., 2001). IL-4 signals through 
both the type I and type II receptor complexes whereas IL-13 
signals only through the type II complex, because IL-13 binds to 
IL-13Rα1, whereas IL-4 primarily binds to IL-4Rα (McKenzie et 
al., 1999). In addition, the two cytokines have different functions 
and signaling. IL-4Rα, γc, and IL-13Rα1 all contain proline rich 
regions that can bind the Janus kinases JAK1, JAK2, JAK3, and 
TYK2. In hematopoietic cells that express γc and the associated 
JAK3, IL-4 binding to type I receptor results in the activation 
of JAK1, JAK2, and JAK3 (Hershey, 2003; Bhattacharjee et al., 
2013). IL-4 and IL-13 binding to type II receptor activate JAK1, 
JAK2, and TYK2. Activation of JAKs results in phosphorylation 
of cytoplasmic tyrosines leading to the recruitment of STAT6 to 
the receptor, followed by its phosphorylation and activation. The 
activation of STAT6 is the primary signaling event in the response 
to IL-4 or IL-13 (Cao et  al., 2016). In certain experimental 
conditions STAT1 and STAT3 can also be activated by both IL-4 
and IL-13 (Wang et al., 2004; Bhattacharjee et al., 2013; Pham et 
al., 2019). The cytoplasmic domain of human IL-13Rα1 contains 
two tyrosine residues, which might serve as docking sites for 
STAT3 (Hershey, 2003). Phosphorylated STAT6 and STAT3 
monomers dimerize and then translocate to the nucleus, bind to 
specific DNA elements to regulate transcription (Bhattacharjee 
et al., 2013).
FIGURe 1 | Schematic representation of the three receptors that bind IL-4, IL-13, or both. Type I receptor is composed of the IL-4Rα subunit complexed with 
common γc. This receptor, expressed on hematopoietic cells, binds to IL-4. Ligand binding by type I receptor complex leads to activation of Janus family kinases 
(JAK1, JAK2, and JAK3) and subsequent phosphorylation of signal transducer and activator transcription 6 (STAT6). Type II receptor consists of IL-4Rα complexed 
with IL-13Rα1 and is found in many non-hematopoietic cells (e.g., bronchial epithelial cells, smooth muscle cells, fibroblasts, keratinocytes). Ligand binding type II 
receptor complex leads to activation of JAK1, JAK2, and tyrosine kinase 2 (TYK2) and subsequent phosphorylation of STAT6 and STAT3. Activation of JAKs leads 
to the recruitment of STATs to the receptors, followed by STAT phosphorylation and dimerization. Activated STAT dimers translocate to the nucleus, bind specific 
DNA elements, and initiate activation of downstream genes. IL-4 signals through both type I and type II receptors, whereas IL-13 signals only through type II 
receptor. IL-13 also binds to a third IL-13Rα2 receptor whose functions are largely unknown. Under certain circumstances, IL-13 signaling through IL-13Rα2 results 
in phosphorylation of ERK1/2 in a STAT6-independent manner and the formation of the dimeric transcription factor AP-1. Phosporylated AP-1 translocates to the 
nucleus and bind to specific DNA elements.
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LaPorte and collaborators have examined in detail the molecular 
and structural basis of the IL-4/IL-13 receptor system (LaPorte et al., 
2008). They demonstrated that IL-4 first binds to IL-4Rα to form a 
binary complex which then binds to the γc to form the functional 
ternary complex (type I receptor). IL-4 and IL-13 can also bind 
with high affinity to IL-4Rα and IL-13Rα1, respectively (type II 
receptor). The authors also compared the kinetics and potency of 
IL-4 and IL-13 signaling. IL-4 induced tyrosine phosphorylation 
of STAT6 more rapidly and more potently than IL-13. The latter 
observation was supported by previous experiments on cultured 
airway smooth muscle cells (Laporte et al., 2001). IL-4 is a central 
mediator for Th2 cell polarization, initiation of IgE synthesis, and 
recruitment of eosinophils (Chatila, 2004; Wynn, 2015). Although 
IL-13 has some redundancy in these effects, this cytokine has 
additional roles in mediating goblet cell hyperplasia, airway 
smooth muscle contractility, collagen deposition, and fibrosis 
(Gour and Wills-Karp 2015).
There is a distinct IL-13Rα2 subunit, to which only IL-13 
binds (Chen et al., 2009). Initially this receptor was considered 
a decoy receptor (Ingram and Kraft, 2012) involved in 
removing IL-13 by internalization (Wood et al., 2003; Lupardus 
et al., 2010; Kasaian et al., 2011). Although the IL-13Rα2 lacks 
canonical JAK-STAT signaling activity (Kawakami et al., 2001), 
this hypothesis has come into question because several studies 
have shown that, under certain circumstances, IL-13Rα2 can 
mediate IL-13 signaling (Fichtner-Feigl et al., 2006; Fujisawa 
et al., 2009; He et al., 2013). In human airways, it was found 
that IL-13Rα2 is involved in IL-13 signaling through the 
transcription factor activator protein-1 (AP-1) to induce the 
activation of TGF-β (Fichtner-Feigl et al., 2006). Recently, it 
has been demonstrated that IL-13 induced phosphorylation of 
ERK1/2 and the downstream activation of AP-1-related genes 
in human nasal epithelial cells (Liu et al., 2018). The authors 
proposed that engagement of IL-13Rα2 by IL-13 activates 
FIGURe 2 | Schematic representation of the cellular sources of IL-13 (red arrows) and its effects of immune and structural cells in asthma (black arrows). Different 
stimuli (allergens, superallergens, pollutants, viral and bacterial products, etc.) activate epithelial cells which release several cytokines (e.g., thymic stromal 
lymphopoietin, IL-33, IL-25). These mediators activate a variety of immune cells (ILC2, Th2 cells, mast cells, macrophages, basophils, eosinophils, B cells) which 
produce several cytokines including IL-13. IL-13 modulates the functions of IL-13+ ILC2, mast cells, macrophages, eosinophils, and B cells. This cytokine induces 
goblet cell hyperplasia and mucus production, airway smooth muscle cell hyperplasia and proliferation, fibroblast activation and collagen deposition, macrophage 
polarization (M2) and B cell activation and immunoglobulin E production. These effects of IL-13 are mediated by the engagement of type II IL-13 receptor (IL-13Rα1/
IL-4Rα expressed on these cells). IL-13, as well as IL-4, can activate sensory neurons through the engagement of type II receptor. Tralokinumab, an anti-IL-13 
human IgG4 monoclonal antibody, binds IL-13, thus preventing it from binding to both IL-13Rα1 and IL-13Rα2 on target cells.
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mitogen-activated protein ERK1/2 pathway and downstream 
AP-1-related gene C-JUN.
Figure 2 shows schematically that IL-13 is produced by several 
immune cells and has many diverse functions on a wide variety of 
cell types relevant to the pathogenesis of allergic disorders. IL-13 can 
be produced by activated ILC2 (Shimokawa et al., 2017; Wallrapp 
et al., 2018), Th2 cells (Finkelman et al., 2004; Wynn, 2015), mast 
cells (Burd et al., 1995; Fushimi et al., 1998; Varricchi et al., 2019), 
macrophages (Hancock et al., 1998), basophils (Gibbs et al., 1996; 
Ochensberger et al., 1996; Redrup et al., 1998; Patella et al., 2000; 
Genovese et al., 2003), eosinophils (Schmid-Grendelmeier et al., 
2002; Varricchi et al., 2018a), and B cells (Hajoui et al., 2004). In 
human B cells IL-13 has similar effects as IL-4, including promoting 
B cell proliferation and inducing class switching to IgE and IgG4 
in combination with CD40/CD40L (Oettgen and Geha, 2001) 
and inducing expression of the low-affinity IgE receptor CD23 
(Punnonen et al., 1993; Gould and Sutton, 2008). In macrophages 
IL-13 favors the M2 polarization (Martinez-Nunez et al., 2011; 
Bhattacharjee et al., 2013). IL-13 promotes survival, activation, 
and recruitment of eosinophils (Luttmann et al., 1996; Horie et al., 
1997; Pope et al., 2001). In addition, IL-13 stimulates eosinophil 
trafficking from the peripheral blood to the site of inflammation 
by inducing the production of IL-5 and eosinophil chemokines 
such as eotaxins (Webb et al., 2000; Rosenberg et al., 2007) IL-13 
promotes FcεRI expression and proliferation of human mast 
(Nilsson and Nilsson, 1995; Kaur et al., 2006).
IL-13 also has important effects on non-hematopoietic cells, 
including endothelial cells, smooth muscle cells, fibroblasts, 
epithelial cells, and sensory neurons. IL-13 is a potent inducer 
of vascular cell adhesion molecule-1 (VCAM-1) on endothelial 
cells, an important aspect in the recruitment of eosinophils 
(Bochner et al., 1995). In addition, IL-13 increases the expression 
of ß1 integrin and VCAM-1 on human lung fibroblasts (Doucet 
et al., 1998) and increases muscular contraction in response 
to acetylcholine (Laporte et al., 2001; Grunstein et al., 2002). 
Furthermore, IL-13 enhances proliferation and cholinergic-
induced contraction of smooth muscle cells (Wills-Karp, 
2001) and induces collagen synthesis in human fibroblasts 
contributing to airways remodeling. In epithelial cells, IL-13 
is a potent inducer of eotaxin (Li et al., 1999). Moreover, IL-13 
induces mucus overproduction and goblet cell metaplasia 
(Kuperman et  al., 2002; Kondo et al., 2006). IL-13 induces 
vascular endothelial growth factors (VEGFs) (Corne et al., 
2000) which are pro-angiogenic factors relevant in bronchial 
asthma (Detoraki et al., 2009; Detoraki et al., 2010; Varricchi 
et al., 2018b). Recently, it has been demonstrated that IL-13 and 
IL-4 directly activate mouse and human sensory neurons which 
express IL-13Rα1 and IL-4Rα (Oetjen et al., 2017).
Interleukin 13 in experimental Models  
of Asthma
Seminal studies in animal models of allergic asthma 
demonstrated that selective neutralization of IL-13 reduced 
airway hypersensitivity (AHR), bronchoalveolar lavage (BAL) 
eosinophils, and mucus overproduction (Grunig et al., 1998; 
Wills-Karp et al., 1998). Furthermore, IL-13 delivery to the 
airways caused all of these effects (Grunig et al., 1998; Wills-Karp 
et al., 1998). Overexpression of IL-13 in the lung of mice caused 
mucus hypersecretion, subepithelial fibrosis, eotaxin production, 
and eosinophilic infiltration (Zhu et al., 1999). Interestingly, mice 
with targeted deletion of IL-13 failed to develop allergen-induced 
AHR, despite the presence of eosinophilic pulmonary infiltration 
(Walter et al., 2001). Mice lacking STAT6 were protected from 
pulmonary effects of IL-13 (Kuperman et al., 2002). Importantly, 
reconstitution of STAT6 in epithelial cells only was sufficient 
for IL-13-induced AHR and mucus production in the absence 
of inflammation and fibrosis. Administration of anti-IL-13 in a 
mouse model of chronic asthma inhibited eosinophil recruitment 
in the airways, goblet cell hyperplasia, and subepithelial fibrosis, 
but only marginally inhibited AHR (Kumar et al., 2004). In 
another study, blockade of IL-13 with sIL-13Rα2-human IgG 
fusion protein inhibited AHR associated with brief allergen 
exposure, but did not modify AHR associated with chronic 
airway remodeling (Leigh et al., 2004).
An IL-13 vaccine prepared by inserting a murine IL-13 
peptide into a viral carrier protein, induced sustained and 
intense anti-IL-13 IgG antibodies (Ma et al., 2007), associated 
with inhibition of ovalbumin (OVA)-induced acute airway 
allergic responses. In a more recent study, the same experimental 
approach suppressed BAL IL-13 concentration and eosinophils, 
subepithelial collagen deposition, and mucus hyperproduction 
(Ma et al., 2013). Interestingly, while IL-13 vaccine inhibited 
AHR development, it did not revert AHR. The latter findings 
suggest that IL-13 may be crucial in the development, but not in 
the maintenance of airway hyperesponsiveness.
Il13ra2 gene silencing or blockade of IL-13Rα2 signaling 
led to marked downregulation of TGF-β1 production and 
collagen deposition in a model of lung fibrosis (Fichtner-Feigl 
et al., 2006). In IL-13Rα2-deficient mice, AHR and airway 
inflammation (i.e., mucus production and BAL eosinophils) 
were attenuated compared to wild type mice following house 
dust challenge (Chen et al., 2013). More recently, it was reported 
that, in IL-4Rα-deficient mice, IL-13, but not IL-4, was required 
for development of OVA-mediated AHR and goblet cell 
hyperplasia (Kirstein et al., 2016). Munitz and collaborators 
studying Il13ra1 -/- mice found that IL-13Rα1 is critical for 
baseline IgE production, AHR, mucus production, and eotaxin 
production. By contrast, Th2 and IgE responses to antigen were 
IL-13Rα1-independent (Munitz et al., 2008).
In a novel mouse model of non-allergic asthma overexpression 
of the activator protein-1 (AP-1) subunit Fra2, caused airway 
inflammation with IL-13 overexpression, BAL eosinophilia, 
mucus hyperproduction, AHR, and peribronchial collagen 
deposition (Gungl et al., 2018). Administration of anti-IL-13 
antibody markedly decreased STAT6 phosphorylation in the 
lung, BAL eosinophilia, and goblet cell hyperplasia. However, 
peribronchial collagen deposition and bronchial smooth muscle 
width were not affected by anti-IL-13 administration. The 
interesting results obtained in this experimental model may be 
more reflective of severe asthma which exhibit poor response to 
mAb anti-IL-13.
Genetic deletion of the IL-33 receptor in a mouse model 
of experimental asthma increased TSLP production, which 
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stimulated the emergence of IL-13+ ILC2s and lung mast cells 
leading to airway hyperresponsiveness (Verma et al., 2018).
Collectively, the results derived from different experimental 
models indicate that IL-13 plays an important role in the 
development of several aspects of asthma. However, it is 
becoming evident that IL-13 neutralization is not sufficient 
to reverse certain aspects of airway inflammation once they 
are established.
Interleukin 13 expression in Asthmatic 
Patients
Increased concentration of IL-13 have been found in the blood 
(Alasandagutti et al., 2017), sputum, bronchial mucosa (Berry 
et al., 2004), and BAL fluid (Prieto et al., 2000) of asthmatic patients 
compared to healthy individuals. Increased IL-13 expression in 
asthma was confirmed by IL-13 mRNA overexpression (Truyen 
et al., 2006) and by ex vivo stimulation of sputum T cells (Boniface 
et al., 2003). Following allergen challenge, IL-13 is increased in 
BAL (Huang et al., 1995; Kroegel et al., 1996). Ex vivo BAL T cells 
express IL-13 mRNA (Bodey et al., 1999); expression is inversely 
related to forced expiratory volume in 1 s (FEV1) (Barcelo et al., 
2006). Several studies have shown that IL-13 is expressed in 
bronchial biopsies in patients with asthma (Kroegel et al., 1996; 
Naseer et al., 1997; Berry et al., 2004; Saha et al., 2008). IL-13+ ILC2 
were increased in the circulation of asthmatic patients with levels 
correlating with asthma severity (Jia et al., 2016). High production 
of IL-13 by cord blood CD4+ T cells is a predictor of development 
of atopic disorders (Martinez 2002).
Polymorphisms in the Interleukin 
13/Interleukin 4 Receptor Complex 
Associated with Asthma
Polymorphisms have been identified both in the IL-13 promoter 
(IL-13-1112 T) and the coding region (IL-13+Arg 130Gen, 
IL-13+2044G > A) in asthmatic patients (Hershey et al., 1997; 
Graves et al., 2000; Heinzmann et al., 2000; Arima et al., 2002; 
Cameron et al., 2006). One of the polymorphisms (Arg 130 
Gln) (A/G) identified occur in the region critical for receptor-
ligand interactions. Multiple polymorphism in IL-4R gene 
have also been identified and associated with asthma (Hershey 
et al., 1997; Kruse et al., 1999; Ober et al., 2000). Recently, three 
meta-analyses of IL-13 polymorphisms in adults and children 
suggested that the IL-13+1923 C/T polymorphism is associated 
with increased risk of asthma (Liu et al., 2014; Mei and Qu, 2017; 
Xu et al., 2017).
Tralokinumab and Lebrikizumab for the 
Treatment of Severe Uncontrolled Asthma
Several anti-IL-13 mAbs (anrukinzumab, lebrikizumab, 
tralokinumab) have provided an opportunity to investigate the 
role of this cytokine in the pathophysiology of severe asthma, as 
well as assessing treatment response. A phase 1 study evaluated 
the pharmacokinetics, safety, and tolerability of tralokinumab in 
asthmatic patients receiving three different i.v. doses: 1 mg/kg, 5 
mg/kg, or 10 mg/kg (Singh et al., 2010). Despite the small sample 
size, pharmacokinetics were linear over the dose range studied. 
The half-life was found to be 2–3 weeks and tralokinumab 
exhibited an acceptable safety profile.
A phase 2a, randomized, double-blind, placebo-controlled, 
parallel-group, multicenter study investigated the effects of 
different dose regimens of tralokinumab in 194 adults with 
moderate-to-severe asthma inadequately controlled with 
standard therapy (Piper et al., 2013). Three dose regimens were 
evaluated: 47 patients received s.c. tralokinumab 150 mg, 51 
patients received tralokinumab 300 mg, 48 subjects received 
tralokinumab 600 mg, and 48 patients received placebo. The 
primary endpoint was the change from baseline in mean Asthma 
Control Questionnaire score (ACQ-6) at week 13. Secondary 
endpoints were change in FEV1, pre-bronchodilator lung function, 
patient-reported outcomes (PROs), rescue β2-agonist use, and 
safety outcomes. Mean ACQ-6 score improved in all treatment 
groups, from baseline to week 13. These changes in ACQ-6 
persisted through week 24 and were greater in active patients 
with higher IL-13 sputum concentrations compared with subjects 
with lower IL-13 sputum concentrations or subjects receiving 
placebo. Improvement in FEV1 were higher in patients with 
peripheral eosinophil counts ≥ 300 cells/ml. Pulmonary function 
improvements were higher in tralokinumab patients with higher 
sputum IL-13 (≥ 10 pg/ml-1) compared to tralokinumab patients 
with lower sputum IL-13 (≤10 pg/ml-1) and patients receiving 
placebo. However, there was no significant difference in asthma 
exacerbation rate. The authors defined asthma exacerbations as 
either a progressive increase of asthma symptoms (cough, wheeze, 
chest tightness, and/or shortness of breath) or a reduction 
of >20% in peak expiratory flow or FEV1 from baseline that did 
not resolve after the initiation of rescue medications and resulted 
in an administration of systemic glucocorticoids.
The phase 2b clinical trial run by Brightling and colleagues 
evaluated safety and tolerability profile and the reduction in 
exacerbation rate and FEV1 improvement (Brightling et al., 
2015). The authors randomized 452 severe asthmatic patients, 
all with two-to-six asthma exacerbations in the previous year, to 
receive tralokinumab (300 mg s.c. either every 2 weeks or every 
2 weeks for 3 months and then every 4 weeks) or placebo as 
add-on therapy for 1 year. At the end of the study, they reported 
no changes in the annual exacerbation rate at week 52 (primary 
endpoint) in patients treated with tralokinumab, either every 2 
or 4 weeks, versus placebo or in time to first exacerbation. The 
authors defined asthma exacerbation as an increase in asthma 
symptoms resulting in use or increase in dose of systemic 
glucocorticoids for three or more consecutive days. Similarly, 
secondary endpoints such as improvements in prebronchodilator 
FEV1, ACQ-6, and AQLQ(S) were not significant in patients 
treated with tralokinumab compared with placebo. They found 
a significant improvement in FEV1 in patients treated with 
tralokinumab every 2 weeks. In this study measurement of serum 
dipeptidyl peptidase-4 (DPP-4) and periostin concentrations 
were included as a predictive candidate biomarkers before the 
study was unmasked. Subgroup analyses of patients receiving 
tralokinumab every 2 weeks with airway reversibility at baseline, 
but not receiving oral glucocorticoids, showed some clinical 
improvements in the subgroup who had raised serum DPP-4 
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and periostin (Brightling et al., 2015). These preliminary results 
suggested that certain subpopulations of patients with severe 
asthma might respond to tralokinumab treatment.
A phase 2 multicenter, double-blind, randomized, placebo-
controlled trial evaluated the effects of tralokinumab on 
eosinophilic airway inflammation in uncontrolled moderate-
to-severe asthma (MESOS) (Russell et al., 2018). In this study, 
participants aged 18–75 years were randomly assigned to receive 
tralokinumab (300 mg s.c. every 2 weeks) or placebo. The 
primary outcome measure was change from baseline to week 
12 in bronchial biopsy eosinophil count. Secondary outcome 
measures included change in blood and sputum eosinophil 
counts. Exploratory outcomes included FeNO and blood 
IgE concentrations. Tralokinumab did not affect bronchial, 
peripheral blood, or eosinophil counts compared to placebo 
at week 12. FeNO concentrations and total blood IgE were 
significantly reduced. The authors concluded that IL-13 is not 
crucial for eosinophilic airway inflammation control in patients 
with moderate-to-severe asthma.
Two large phase 3 clinical trials, STRATOS 1 and STRATOS 2, 
explored the use of periostin and DPP-4 as biomarkers of IL-13-
driven inflammatory patterns in patients aged 12–75 years with 
severe uncontrolled asthma treated with tralokinumab (300 mg s.c. 
every 2 weeks for 52 weeks) or placebo (Panettieri et al., 2018). The 
primary endpoint was the annualized asthma exacerbation rate 
reduction at week 52 in the all-comers population for STRATOS 
1 and in the biomarker-positive population for STRATOS 2. 
The results of both trials confirmed that tralokinumab did not 
improve the annual asthma exacerbation rate in the all-comers 
population with severe asthma. In contrast to the preliminary 
results of the phase 2 trial (Brightling et al., 2015), periostin and 
DPP-4 were not shown to predict response to tralokinumab. In 
both trials, tralokinumab-treated participants had a small increase 
in blood eosinophil counts from baseline, whereas placebo-treated 
participants did not. A recent meta-analysis of six randomized 
clinical trials suggested that tralokinumab was well tolerated and 
modestly improved FEV1 but did not reduce asthma exacerbations 
in severe uncontrolled asthma (Zhang et al., 2019).
Given the need to reduce oral glucocorticoid administration in 
patients with severe asthma, treatments that may allow tapering 
of glucocorticoids without loss of disease control are needed. A 
40-week, randomized, double-blind trial (TROPOS) evaluated 
the oral glucocorticoid-sparing potential of tralokinumab in 
patients with severe, uncontrolled asthma requiring maintenance 
glucocorticoid treatment plus ICS/LABA (Busse et al., 2019). One 
hundred forty patients were randomized to tralokinumab (300 
mg s.c. every 2 weeks) or placebo. The primary endpoint was 
percentage change from baseline in average glucocorticoid dose at 
week 40, while maintaining asthma control. Secondary endpoints 
included patients with a prescribed maintenance glucocorticoid 
dose of ≤ 5 mg, those with greater than 50% reduction in prescribed 
maintenance glucocorticoids dose and annual asthma exacerbation 
rate. An asthma exacerbation was defined as worsening of asthma 
that required a temporary increase in systemic glucocorticoids for 
⩾3 days or that resulted in an emergency-room or urgent-care 
visit that led to a temporary increase in systemic glucocorticoids 
for ⩾3 days to treat symptoms or an inpatient hospitalization due 
to asthma. There were no significant between-group differences 
for primary and secondary endpoints. Reporting of adverse events 
and serious adverse events were similar for the tralokinumab and 
placebo groups.
A randomized, double-blind, placebo controlled study 
examined the effects of another anti-IL-13 mAb, lebrikizumab 
(250 mg s.c. once monthly for 6 months), on change in 
prebronchodilator FEV1 from baseline to week 12 in 219 adults 
with uncontrolled asthma (Corren et al., 2011). Lebrikizumab 
treatment was associated with greater improvement in percent 
change in FEV1 in patients with high pretreatment levels of 
serum periostin compared to patients with low periostin levels. 
In two replicate studies (LUTE and VERSE) in patients with 
moderate-to-severe uncontrolled asthma, lebrikizumab (37.5, 
125 or 250 mg s.c. every 4 weeks) reduced asthma exacerbation 
rate by 60% compared to placebo in periostin-high patients 
and by 5% in periostin-low patients (Hanania et al., 2015). 
In these studies the authors defined asthma exacerbation as 
new or increased asthma symptoms that led to treatment with 
systemic glucocorticoids or to hospitalization. Two replicate, 
phase 3 trials (LAVOLTA1 and LAVOLTA2) explored the use 
of periostin and eosinophilia (≥ 300 cells/µl) as biomarkers 
of IL-13-driven inflammatory patterns in patients with severe 
uncontrolled asthma treated with lebrikizumab (37.5 mg or 125 
mg s.c. once every 4 weeks for 52 weeks or placebo) (Hanania 
et al., 2016). The primary endpoint was the reduction in the 
rate of asthma exacerbations over 52 weeks in biomarker-high 
patients (periostin ≥ 50 ng/ml or blood eosinophils ≥ 300 
cells/µl. In contrast to the preliminary results of phase 2 trials 
(Corren et al., 2011; Hanania et al., 2015), lebrikizumab did not 
consistently show significant reduction in asthma exacerbations 
in biomarker-high patients.
Anti-Interleukin 13 in Nasal Polyposis
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a 
common and relevant comorbidity for severe asthma (Heffler 
et al., 2013). The prevalence of CRSwNP is greater in asthmatics 
compared to the general population (Settipane and Chafee, 
1977) and it increases with the severity of asthma (Pearlman 
et al., 2009; Lin, 2011), with the highest prevalence rates in 
non-atopic, late-onset, severe asthmatics (Amelink et al., 
2013). More than 60% of patients with CRSwNP have asthma 
(Ragab et al., 2004; Guida et al., 2010). Moreover, CRWwNP 
is one of the significant determinants of poor asthma control 
(Heffler et al., 2013) and a hallmark of refractory eosinophilic 
asthma (Amelink et al., 2013). The clinical evidence of a strong 
relationship between CRSwNP and severe asthma raises the 
possibility of a shared pathogenesis. In particular both diseases 
seem to be dependent on eosinophilic inflammation mediated 
by epithelial cytokines such as thymic stromal lymphopoietin 
(TSLP), IL-25, and IL-33 secreted as a consequence of epithelial 
damage (Boita et al., 2016; Metha 2016; Varricchi et al., 2018c). 
The latter activation is mediated by ILC2 which produce several 
type 2 cytokines such as IL-13 and IL-5 (Aron and Akbari 2017; 
Poposki et al., 2017). Recently, it has been reported that there 
were significant increases in IL-13, IL-13Rα1, and IL-13Rα2 
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mRNA and protein concentrations in nasal polyp epithelium 
(Liu et al., 2018). Moreover, IL-13 treatment resulted in mucus 
overproduction and impairment of ciliary function of human 
nasal epithelial cells. Therefore, an anti-IL-13 strategy, such as 
tralokinumab, may be helpful in the management of patients 
with nasal polyps. Unfortunately, there are no clinical trials 
of treatment of CRSwNP with anti-IL13 mAbs. Interestingly, 
patients treated with dupilumab, a mAb against IL-4Rα, the 
common receptor for both IL-4 and IL-13 had a significant 
reduction in polyp size and improvement in symptoms and 
nasal and olfactory function (Bachert et al., 2016).
CONCLUDING ReMARKS AND 
PeRSPeCTIveS
Three phase 2 clinical trials (Piper et al., 2013; Brightling et al., 2015; 
Russell et al., 2018) and three phase 3 clinical trials (Panettieri et al., 
2018; Busse et al., 2019) have shown that tralokinumab did not lower 
the annual exacerbation rate and did not improve ACQ-6 scores 
compared to placebo in severe uncontrolled asthmatic patients. 
These negative findings parallel the results of two replicate, phase 
3 trials with lebrikizumab (Hanania et  al., 2016). These negative 
results are surprising given the wide spectrum of pro-inflammatory 
and pro-fibrogenic activities of IL-13 in experimental models of 
asthma (Chu et al., 1998; Laporte et al., 2001; Komai et al., 2003; 
Kanoh et al., 2011) and in asthmatic patients (Huang et al., 1995; 
Kroegel et al., 1996; Boniface et al., 2003; Truyen et al., 2006; Saha et 
al., 2008; Jia et al., 2016).
There are several possible explanations of these negative 
findings. First, it is likely that IL-13 is not the main cytokine involved 
in the complex network of severe asthma pathogenesis, meaning 
blocking it alone is ineffective. Second, as shown in several trials 
(Brightling et al., 2015; Hanania et al., 2016; Panettieri et al., 2018), 
the biomarkers (e.g., periostin, DPP-4, peripheral eosinophil 
count) used to identify responders to anti-IL-13 therapy are not 
optimal. Third, in both experimental models (Walter et al., 2001) 
and clinical studies (Brightling et al., 2015; Hanania et al., 2016; 
Panettieri et al., 2018) blocking IL-13 appears to have no effect 
on reducing tissue or blood eosinophilia, the pathophysiological 
feature most closely linked to asthma exacerbations. Fourth, 
perhaps the route of administration (i.e., s.c.) and the size of the 
anti-IL-13 mAb particles are not ideal. For instance, it has been 
reported the preliminary efficacy of a nebulized inhaled anti-IL-13 
mAb antigen-binding fragment in macaque model of asthma 
(Lightwood et al., 2018). Finally, we cannot exclude the possibility 
that some of these negative findings could be due to the inclusion 
in clinical trials of patients with Th2-low asthma.
Interestingly, the initial attempts to develop cytokine therapies for 
asthma focusing on antagonizing IL-4 were also unsuccessful (Hart 
et al., 2002; Steinke 2004), as was an attempt to block the combined 
receptor (Wenzel et al., 2007; Burmeister Getz et  al., 2009). By 
contrast, dupilumab, which binds to IL-4Rα and consequently blocks 
both IL-4 and IL-13 signaling, decreases asthma exacerbations and 
improves respiratory symptoms in patients with persistent asthma 
(Castro et al., 2018; Rabe et al., 2018). These observations suggest 
that only the effective simultaneous blockade of signaling from two 
main cytokines (i.e., IL-4 and IL-13) is effective in the treatment 
of severe asthma. Using allergic preclinical models, it has been 
demonstrated that the combined blockade of the IL-13 and IL-33 
pathways leads to a greater inhibition of type 2 inflammation 
over inhibition of either pathway alone (Ramirez-Carrozzi et al., 
2017). Similarly, co-blockade of IL-13 and IL-25 attenuated AHR, 
eosinophil infiltration in the lung, and mucus hyperproduction in a 
mouse model of OVA-induced asthma (Zhang et al., 2017). Recently, 
a novel dual antagonist anti-TSLP/IL-13 bispecific antibody has 
been described (Venkataramani et al., 2018). It will be interesting to 
see whether combinatorial blockade of multiple cytokines, including 
IL-13, may yield additional efficacy over single-axis therapies alone.
It is intriguing that IL-13 blockade modulates several aspects 
of different experimental models of allergic asthma (Laporte et al., 
2001; Walter et al., 2001; Komai et al., 2003; Munitz et al., 2008; 
Chen et al., 2013; Ma et al., 2013; Chachi et al., 2017). Moreover, 
recent results demonstrate that anti-IL-13 antibody improves 
bronchial hyperresponsiveness and mucus production in a 
mouse model of non-allergic asthma (Gungl et al., 2018). These 
positive experimental results contrast with negative results in the 
treatment of asthmatic patients with different anti-IL-13 mAbs 
(tralokinumab and lebrikizumab) (Piper et al., 2013; Brightling et 
al., 2015; Hanania et al., 2016; Panettieri et al., 2018; Russell et al., 
2018; Busse et al., 2019). These findings highlight that the results 
from murine studies do not always predict clinical effectiveness.
In conclusion, despite several efforts, attempts to demonstrate 
a benefit of anti-IL-13 in patients with severe asthma remain 
unproven. While this may be because the right predictive 
biomarkers or patient phenotypes have not yet been identified, 
it is perhaps more likely that there is enough redundancy in the 
pathophysiology of severe asthma to persist without IL-13. This 
is not to say, at this stage, that another clinical indication might 
not be found for IL-13-blocking drugs in future.
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